Notice from Nevada State Board of Pharmacy - On December 29, 2022, Congress signed into law with the Consolidated Appropriations Act of 2023 (the Act), which eliminated the “DATA-Waiver Program.” The Act removes the federal requirement for practitioners obtain a Data-Waiver (X-waiver) to prescribe medications such as buprenorphine, a Schedule III controlled substance, for the treatment of opioid use disorder (OUD). On January 12, 2023, the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) announced the immediate elimination of the X-Waiver for prescribing buprenorphine. The elimination of the X-waiver will increase the number of practitioners eligible to prescribe buprenorphine thereby increasing access to buprenorphine for those in need.